This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
High-Specific-Activity I-131 MIBG for Advanced Pheochromocytoma and Paraganglioma

High-Specific-Activity I-131 MIBG for Advanced Pheochromocytoma and Paraganglioma

Format

Webcast

Time to Complete

1 hour

Released

July 30, 2019

Expires

July 30, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour

Accredited Providers

This activity is jointly provided by Haymarket Medical Education and AKH Inc., Advancing Knowledge in Healthcare.

Commercial Supporter

Supported by an educational grant from Progenics Pharmaceuticals, Inc.

Program Description

Because of the catecholamine-secreting nature of these tumors, pheochromocytomas and paragangliomas (PPGLs) can manifest in various serious symptoms and signs that often go undiagnosed or misdiagnosed. More than 100 symptoms and signs have been described in association with these tumors, including but not limited to hypertension, headaches, hyperglycemia, palpitations, nausea, pain, vomiting, anxiety, and diaphoresis. Because of the delay in diagnosis, patients often present with large tumors and/or distant metastases, and patients endure significant burdens resulting from hormonal dysfunction and tumor progression. Furthermore, the treatment of PPGL can be challenging. Fortunately, an improved understanding of PPGL is leading to better diagnostic evaluation, more appropriate patient-specific treatment strategies, and improved patient outcomes. The recently US Food and Drug Administration (FDA)-approved iobenguane iodine-131 (I-131) may have high specific activity (HSA) and little to no unlabeled meta-iodobenzylguanidine (MIBG), potentially providing an advantage over conventional I-131 MIBG in the PPGL setting.

This activity will inform clinicians who treat patients with PPGL of the therapeutic potential of the newest HSA I-131 MIBG, which was added to the treatment armamentarium less than 1 year ago.

Intended Audience

Nuclear medicine physicians, radiologists, radiation oncologists, medical oncologists, cardiologists, endocrinologists, nurse practitioners (NPs), physician assistants (PAs), nurses, radiology technicians, and medical physicists

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Recognize the signs and symptoms of pheochromocytoma/paraganglioma in patients and properly evaluate patients to make a definitive diagnosis
  • Appreciate the typical natural history of a pheochromocytoma/paraganglioma patient
  • Specify the available imaging options for pheochromocytoma/paraganglioma and understand their appropriate applications
  • Explain the selection criteria and technical considerations for radiopharmaceutical therapy of pheochromocytoma/paraganglioma
  • Conflict Of Interest Disclosure Policy

    In accordance with the ACCME Standards for Commercial Support, Haymarket Medical Education (HME) and AKH Inc., Advancing Knowledge in Healthcare (AKH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME and AKH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

    Faculty

    Camilo Jimenez, MD
    Professor
    Department of Endocrine Neoplasia and
      Hormonal Disorders
    Division of Internal Medicine
    The University of Texas MD Anderson
      Cancer Center
    Houston, TX

    Dr. Jimenez is the principal investigator for Progenics Pharmaceuticals, Inc.

    Daniel A. Pryma, MD
    Associate Professor of Radiology &
      Radiation Oncology
    Chief, Division of Nuclear Medicine &
      Clinical Molecular Imaging
    Department of Radiology
    Perelman School of Medicine
    University of Philadelphia
    Philadelphia, PA

    Dr. Pryma receives consulting fees and contracted research grants from Progenics Pharmaceuticals, Inc.

    Accredited Providers Disclosures

    Haymarket Medical Education and AKH Inc., Advancing Knowledge in Healthcare staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

    Reviewer Disclosures

    The independent content reviewer, Ruchit Parikh, PharmD, and AKH Inc., Advancing Knowledge in Healthcare staff, Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner, have no relevant financial relationships to disclose.

    Credit

    1.00

    Type

    AMA PRA Category 1 Credit(s)TM

    Accreditation Statement

    Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Designation Statement

    Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit

    1.00

    Type

    CNE Contact Hour(s)

    Accreditation Statement

    AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    Designation Statement

    This activity is awarded 1.00 contact hour.

    Additional Credit Information

    Physician Assistant Continuing Education
    AAPA accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.

    Nurse Practitioner Continuing Education
    AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

    Disclosure of Unlabeled Use

    This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

    Disclaimer

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education, AKH Inc., Advancing Knowledge in Healthcare, or Progenics Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    If you have any questions relating to the CME accreditation of this activity, please contact HME at cmequestions@haymarketmedical.com.

    If you have any questions relating to the CE or ACPE accreditation of this activity, please contact AKH at jgoldman@akhcme.com.

    If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

    Instructions

    To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

    SYSTEM REQUIREMENTS

    Hardware and Software Requirements
    • A computer with an internet connection
    • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
    • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
    Add to Queue